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Abstract
The coupling of peptides to polyglycerol carriers represents an important route towards the multivalent display of protein ligands.
In particular, the inhibition of low affinity intracellular protein–protein interactions can be addressed by this design. We have
applied this strategy to develop binding partners for FBP21, a protein which is important for the splicing of pre-mRNA in the
nucleus of eukaryotic cells. Firstly, by using phage display the optimized sequence WPPPPRVPR was derived which binds with
KDs of 80 μM and 150 µM to the individual WW domains and with a KD of 150 μM to the tandem-WW1–WW2 construct.
Secondly, this sequence was coupled to a hyperbranched polyglycerol (hPG) that allowed for the multivalent display on the surface
of the dendritic polymer. This novel multifunctional hPG-peptide conjugate displayed a KD of 17.6 µM which demonstrates that the
new carrier provides a venue for the future inhibition of proline-rich sequence recognition by FBP21 during assembly of the
spliceosome.
Introduction
Pre-mRNA splicing is an important step in the expression of
eukaryotic genes, during which non-coding elements are
removed from the pre-mRNA and coding elements are ligated
to form a mRNA which can further on be translated into
protein. The use of alternative splice sites represents a means to
enhance the post-transcriptional diversity of transcripts and ulti-
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mately of the proteome of eukaryotic species. Alternative
splicing is rare in yeast but a commonality in higher eukaryotes,
for which the existence of different splice isoforms is the rule
rather than the exception [1]. Aberrant splicing is associated
with several diseases [2] and the inhibition of splicing factors
has become a recent topic in the field of antitumor drugs [3].
Formin-binding protein 21 (FBP21) has been detected as a
component of early spliceosomal complexes and more specifi-
cally was shown to interact with proline–arginine-rich peptides
in the core splicing protein SmB/B’ and the U2-associated
protein SF3B4. The interaction of FBP21 with these proteins is
conferred by two WW domains that are connected by a short, 8
amino acid long linker sequence. Multivalent recognition of the
proline-rich sequences (PRS) by the tandem-WW domains was
shown to boost overall affinity, while still keeping the inter-
action highly dynamic [4,5]. FBP21 was shown to enhance
splicing of a reporter construct in living cells [4] while another
study suggested that the protein is involved in the alternative
splicing of vascular endothelial growth factor (VEGF). In the
same study, the natural compound borrelidin was suggested to
confer its splicing inhibition function by directly binding to the
WW domains of FBP21 [6]. Here, we have taken a different ap-
proach to inhibit binding of FBP21-tWW to proline-rich
sequences in the spliceosome, where the optimization
of a peptide ligand by phage screening and subsequent
multivalent display on a dendritic polymer is combined to
create higher affinity binders with the potential to be used in
cellular studies.
Dendritic polyamines such as polyglycerol amine [7,8], poly-
ethyleneimine [9,10], and polyamidoamine [11] are taken up by
the cell and localize to endosomes or endolysosomes, where
they lead to proton pumping and concomitant influx due to a
proton sponge effect [12], increasing the ionic strength in these
organelles. Eventually, this leads to osmotic rupture of the
endosome and release of the dendritic polymer into the cyto-
plasm [13]. These polymeric scaffolds have been explored well
for tumor targeting by using polymer-drug conjugates or poly-
plexes with genes or siRNA [14], but also have the potential to
inhibit protein–protein interaction in cells, by displaying
multiple ligands for a target protein. The hyperbranched polyg-
lycerol amine (hPG-NH2) with different degrees of amine func-
tionalization can easily be prepared from hPG-OH with high
yields in three steps, as reported in the literature [15]. It can be
used for peptide coupling, while it is still maintaining the
minimal positive charge on the carrier polymeric backbone
which is necessary for cell penetration. The hPG-NH2 1 with
70% amine functionalization was chosen to conjugate multiple
copies of an optimized targeting peptide, yielding the multiva-
lent hPG-peptide conjugate 2. The dissociation constant (KD) of
the interaction between hPG-peptide conjugate 2 and
FBP21-tWW was measured by isothermal titration calorimetry
(ITC) and compared to the KD of the interaction between the
monovalent peptide and FBP21-tWW to analyze if multivalent




In order to determine an optimal peptide sequence for a
FBP21-tWW ligand, we conducted a phage display experiment
for each of the two WW domains. Phages used in these experi-
ments carried a randomized X9-peptide fused to phage coat
protein VIII [16]. Enrichment factors were calculated after each
selection cycle, and reached a plateau after four panning rounds.
Phagemids were isolated and sequenced after the third and
fourth panning rounds. The sequences for WW1 and WW2
were overlapping to a large extent, showing their similarity in
binding preference. This is expected from evolutionary and
binding studies carried out earlier [17,18]. The sequences
obtained are shown in Figure 1B. In agreement with previous
findings for this group of WW domains a polyproline stretch
and an arginine residue are present in most sequenced clones.
Interestingly, a preference for an aromatic residue N-terminal to
the polyproline stretch could also be observed. To define an
optimized single monovalent binder, we analyzed the affinities
for a selected set of ligands from this panel of sequences with
regard to FBP21’s WW domains by ITC under the same condi-
tions as were used for the phage display. Four of the six
selected peptides showed affinities in the high micromolar
range, while the peptide WPPPPRVPR showed higher affini-
ties for both WW domains. KD values of 155 ± 18 µM and
87.0 ± 3.4 µM were measured for WW1 and WW2, respective-
ly (Figure 1C). The peptide which was found with the highest
frequency in the phage display experiment (RPPCGYPLP), did
not show any binding to either WW domain in ITC experi-
ments, possibly reflecting the potential of the cysteine residue to
form an unspecific complex with glutathione-S-transferase.
Similarly, the peptide RPPPPHFPQ could not be confirmed as a
binder in the ITC experiments. To further analyze which
residues are essential for the interaction, we performed substitu-
tion analyses using peptide SPOT arrays (Figure 1D,
Supporting Information File 1 Figure S1). The experiment gives
some insight into binding specificities. The central role of
proline P5 for binding of peptides is evident for both WW
domains (Figure 1D, Supporting Information File 1 Figure S1).
Proline fulfills two requirements. On the one hand it promotes
formation of the PPII helix conformation, on the other hand, it
is accommodated well into the hydrophobic groove provided by
the individual WW domains [5]. At position P4 proline can be
replaced by leucine, a residue well compatible with the PPII
helical conformation. Arginine is preferred at position 6 or 9,
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Figure 1: Phage display was used to find an optimized binding partner for FBP21-tWW. A) Schematic representation of the phage display workflow:
FBP21-tWW is immobilized and incubated with an X9 phage library. Unbound phages are washed away, then phages expressing a binding peptide
are eluted and amplified to create an enriched library, which is then subjected to another round of panning. Phages were sequenced after 3 and 4
rounds of panning. B) Sequences and frequencies of peptides obtained from eluted phages. Shown in red are the peptides which were chosen for
further analysis. C) Six peptides representing different groups of binding peptides were synthesized and interactions were analyzed using ITC. Shown
are the peptides for which KD values could be determined. D) A substitution analysis showed that in the binding motif of the peptide WPPPPRVPR,
P5 and R9 most strongly contribute to binding of both WW domains. Shown here is the substitution analysis for WW2, the corresponding substitution
analysis for WW1 is shown in Figure S1 (Supporting Information File 1).
highlighting the importance of a positive charge in complex for-
mation. Interestingly, WW1 tolerates an exchange for lysine in
these positions, while WW2 more strictly requires the arginine.
Possibly, the hybrid resonance of the guanidinium group in the
arginine is more important in the case of WW2 compared to
WW1.
The peptide WPPPPRVPR was further on taken as a basis for
exploring the effect of multivalent polymer display. In order not
to restrict binding after coupling by shielding of the C-terminal
arginine, we decided to attach a small linker to the C-terminus
of the derived peptide, yielding the sequence WPPP-
PRVPRGSG.
Synthesis of hPG-peptide conjugate 2
hPG-OH (Mn = 9.0 kDa, PDI = 1.86) was prepared according to
the published procedure [19] (see Figures S2 and S3 in
Supporting Information File 1 for GPC and MALDI–TOF–MS
analysis of the hPG-OH core). Seventy percent of all hydroxy
groups (≈120 OH groups) on hPG-OH were functionalized with
amino groups in a three-step protocol as reported in the litera-
ture [19]. The transformation started from the mesylation of the
hydroxy groups on the hPG. In the next step, the mesylated
polyglycerol was converted to poly(glycerol azide). In the last
step, azide functionalities (N3) were reduced to primary amines
(-NH2) via Staudinger reduction to obtain the desired hPG-NH2
1 (see Figure S4 in Supporting Information File 1 for GPC
analysis of hPG-NH2 1). The appropriate derivative of the
targeting peptide, i.e., Ac-WPPPPRVPRGSG-COOH was acti-
vated by N-hydroxysuccinimidyl ester formation and used for
coupling with hPG-NH2 1 (Mn = 7.3 kDa, PDI = 1.97) to
achieve the hPG-peptide conjugate 2 in good yield as shown in
Scheme 1. Only 5.5% of the amine groups on hPG-NH2 1 were
conjugated with peptide, as determined by 1H NMR analysis,
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Scheme 1: Schematic representation of the synthesis of hPG-peptide conjugate 2.
keeping the rest of amine groups free on hPG-peptide conju-
gate 2 for its cellular penetration properties (see Figures S5 and
S6 in Supporting Information File 1 for the 1H NMR spectra of
the peptide and hPG-peptide conjugate 2). The 5.5% peptide
conjugation accounts for an average of 7.00 peptide units per
polymer.
Analysis of the inhibitory potential of hPG-
peptide conjugate 2
ITC measurements were performed to analyze the dissociation
constant KD of the interaction between FBP21-tWW and hPG-
peptide conjugate 2 in PBS, pH 7.4 (Figure 2A). To compare
the KD values we also analyzed the binding between
FBP21-tWW and the monovalent peptide ligand Ac-WPPP-
PRVPRGSG-COOH (Figure 2B). The KD obtained with the
monovalent ligand was 150 ± 6 μM in solution whereas it was
17 ± 0.016 μM for hPG-peptide conjugate 2, demonstrating an
approximately tenfold overall affinity enhancement. However,
when considering that ≈7 peptides are bound per nanoparticle,
the actual multivalency effect is small.
For both the monovalent ligand and the hPG-conjugate 2, a stoi-
chiometric factor of approximately one was derived from the fit
(1.29 ± 0.0257 for monovalent ligand and tWW, 1.18 ± 0.0221
for tWW and hPG-conjugate 2) suggesting that the observed
affinity is mainly conferred by a one-to-one interaction. For the
hPG-conjugate this means that most peptides on the hPG
particle are not engaged in the interaction with FBP21-tWW.
The enthalpy of the interaction is twice as large for the hPG-
peptide conjugate as for the monovalent ligand, while the
entropy loss upon interaction (−19.5 cal/mol/deg for the inter-
action with the monovalent ligand and −45.9 cal/mol/deg for the
interaction with hPG-peptide conjugate 2) is significantly lower
for the hPG-peptide conjugate, indicating that the hPG scaffold
might impose certain geometric constraints on the interaction
that are not present in the free peptide.
Conclusion
In summary, we have optimized a peptide ligand for the WW
domains of FBP21 and were able to enhance the binding
affinity by presenting it on a multivalent dendritic polyglycerol
scaffold by a factor of ten in comparison to the monovalent
ligand. However, given that on an average seven peptides are
presented on the nanoparticle, this overall enhancement is small
and should be improved in future by varying the ligand density
and size of the hPG-NH2.
Beilstein J. Org. Chem. 2015, 11, 701–706.
705
Figure 2: A) ITC measurement with FBP21-tWW and hPG-peptide conjugate 2, the KD value is 17.6 ± 0.016 μM. B) ITC measurement with
FBP21-tWW and monovalent peptide shows a KD of 150 ± 6 µM.
Supporting Information
Supporting Information File 1
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